Furthermore, mutations in KRAS have been reported as the most common genetic mutations in NSCLC, with mutation rates of approximately 30% (17), yet they were surpassed by the rate of TP53 mutations in our observations. The gene discussed is TP53; the disease is non-small cell lung carcinoma.